Notably, the strengths of this study should be highlighted as follows: (1) Even though previous studies have compared the efficacy of ADA versus ETN in patients with autoimmune diseases, their baseline clinical characteristics are not well balanced, which would affect the reliability of their findings.32, 48. The gene discussed is ADA; the disease is autoimmune disease.